Boston Scientific Faces Weeks-Long Disruption From Cyberattack as Analysts Eye Q3 Impact
Boston Scientific reports a cyberattack detected August 25, 2026, disrupting systems, delaying product shipments worldwide. Full scope still unknown.
/ 491 items
#XY Event-Driven Stocks↓
SK Biopharmaceuticals Licenses Biohaven’s Kv7 Platform in Deal Worth Up to $795 Million
SK Biopharm gains exclusive worldwide rights to Biohaven’s opakalim and Kv7 platform in a deal worth up to $795M, with a possible 2029 U.S. launch.
Phase 2 Data Support TL1A Inhibition in RA, but Spyre Opts Against Monotherapy Priority
Spyre’s RA drug showed benefits and good safety, but results weren’t strong enough to justify developing it as a stand-alone treatment.
McKesson Buys Maryland CRO Precision Medicine Group in $2.25 Billion Deal
Morgan Stanley calls McKesson’s $2.25B Precision Medicine buy a logical CRO addition unlocking a $25B oncology market.
Kura Oncology Chairman and CEO Acquires Additional Company Shares
Kura Oncology CEO Troy Wilson purchased 100,000 shares at a $12.39 weighted average price. This follows a similar buy one week earlier, increasing his direct and trust holdings.
Jazz Pharma Stock Hits All-Time High After FDA Approves Ziihera for Stomach Cancer
The FDA has approved Jazz's Ziihera as a first-line treatment for advanced HER2-positive gastroesophageal adenocarcinoma, establishing a new standard of care.